BioNTech SE ADR buy Ellritze
Start price
28.11.21
/
70%
€321.00
Target price
28.11.22
€400.00
Performance (%)
-25.79%
End price
12.12.21
€238.20
Summary
This prediction ended on 12.12.21 with a price of €238.20. The prediction for BioNTech SE ADR disappointed with a performance of -25.79%. Ellritze has 70% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| BioNTech SE ADR | 7.896% | 7.896% | 243.124% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% |
According to Ellritze what are the pros and cons of BioNTech SE ADR for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
Standard Investments for future growth
Capable Management
Differentiated customer and product portfolio
Top 10 in its market
Cons
Higher risks for its business
High valuation
Comments by Ellritze for this prediction
In the thread Biontech SE diskutieren
Buy mit Kursziel 400,0
In the thread Trading Biontech SE
Stopped prediction by Ellritze for BioNTech SE ADR
BioNTech SE ADR
Start price
Target price
Perf. (%)
€131.05
22.01.22
22.01.22
€150.00
22.01.23
22.01.23
19.38%
06.02.22
06.02.22
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
Standard Investments for future growth
Capable Management
BioNTech SE ADR
Start price
Target price
Perf. (%)
€228.00
25.12.21
25.12.21
€260.00
25.12.22
25.12.22
-15.86%
06.01.22
06.01.22
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
Standard Investments for future growth
Capable Management
BioNTech SE ADR
Start price
Target price
Perf. (%)
€238.20
12.12.21
12.12.21
€260.00
12.12.22
12.12.22
-4.28%
25.12.21
25.12.21
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
Standard Investments for future growth
Capable Management